Search
User Profile
Change
Select your user profile
anti-CD117

anti-CD117 (EP10) Rabbit Monoclonal Primary Antibody
 

Deliver diagnostic confidence in evaluation of GIST

Roche has designed a new Class 1 IVD, anti-CD117 (EP10) Rabbit Monoclonal Primary Antibody reagent for immunohistochemistry testing. anti-CD117 (EP10) is a ready-to-use IHC antibody that enables you to evaluate the expression of CD117 protein with confidence.  The c-KIT gene encodes a transmembrane receptor tyrosine kinase (RTK). CD117 is present in a variety of normal human cell types, including breast epithelium, germ cells, melanocytes, immature myeloid cells and mast cells.1 Along with a panel of antibodies, CD117 immunohistochemistry may aid in the diagnosis of a range of diseases, including gastrointestinal stromal tumors (GISTs)2, mast cell disorders,2 and germ cell neoplasms.1-2

Literature describes the utility of CD117 in the differentiation of GISTs from other mesenchymal tumors along with other biomarkers, such as DOG1 and CD34.3-4

anti-CD117 (EP10) Rabbit Monoclonal Primary Antibody
Specific, intense staining

The new Class l anti-CD117 (EP10) Rabbit Monoclonal Primary Antibody reagent will replace the current Class III Assay, the PATHWAY Anti-c-KIT (9.7) Primary Antibody, allowing for broader use that will suit the current clinical application of CD117.

anti-CD117

 

 

 

 

c-KIT (9.7)
iView Detection
BenchMark XT
instrument

Improved Staining Performance

anti-CD117

 

 

 

 

CD117 (EP10)
OptiView Detection
BenchMark ULTRA
instrument

 

 

 

What’s new?

  • Class I IVD allowing for broader use to suit current clinical application
  • Updated detection protocols with UltraView and OptiView kits
  • For use on BenchMark ULTRA and XT instruments with recommended protocol on the ULTRA
anti-CD117

CD117 and c-KIT

  • NCCN Guideline changes 2019 – should do molecular testing before deciding on treatment path4,
  • Still used to differentiate GIST from other mesenchymal tumors2,3
  • Also used in disease areas outside GIST – seminomas, dysgerminomas, mast cell tumors, myeloma5
View the latest NCCN guidelines updates
anti-CD117

References

1. Rabban, J.T., et al. “Chapter 18 - Immunohistochemistry of the Female Genital Tract.” Diagnostic Immunohistochemistry, 3rd ed., Elsevier, 2010, pp. 722-723.
2. Gibson, P.C., et al. CD117 (KIT): A Diverse Protein With Selective Application in Surgical Pathology. Adv Anat Pathol, 2002, Jan; 9(1): pp. 65-69.
3. Nishida, T., et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer, 2002, 19 pp. 3-14.
4. Wu, C-E., et al. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers, 2019, 11, 679.
5. NordiQC. Assessment Run 56 2019 CD117. https://www.nordiqc.org/downloads/assessments/120_36.pdf Accessed 20 November 2019.